Stocks and Investing
Stocks and Investing
Wed, August 21, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, August 20, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Brian Skorney Maintained (SRPT) at Buy with Decreased Target to $181 on, Aug 20th, 2019
Brian Skorney of Baird, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $202 to $181 on, Aug 20th, 2019.
Brian has made no other calls on SRPT in the last 4 months.
There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 0 agree with Brian's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Brian
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $220 on, Tuesday, July 9th, 2019
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $220 on, Monday, July 1st, 2019
- Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $190 on, Thursday, May 16th, 2019
Contributing Sources